Skip to main content
Fig. 5 | Cardiovascular Diabetology

Fig. 5

From: Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial

Fig. 5

Adverse events by gender in SUSTAIN 6. *On-treatment analysis comprising events with onset from the date of first dose to either the end-of-treatment follow-up visit, the date of last dose plus 42 days, the end-of-trial follow-up visit, or the date of withdrawal from trial, whichever came first (semaglutide males: n = 1007; semaglutide females: n = 635; placebo males: n = 987; placebo females: n = 657). †Full analysis set documented symptomatic hypoglycemia and severe hypoglycemia as defined by the American Diabetes Association [17] (semaglutide males: n = 1013; semaglutide females: n = 635; placebo males: n = 989; placebo females: n = 660). AE adverse event

Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840